scholarly journals A High-Accuracy Model Based on Plasma miRNAs Diagnoses Intrahepatic Cholangiocarcinoma: A Single Center with 1001 Samples

Diagnostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 610
Author(s):  
Jie Hu ◽  
Yi-Ning Wang ◽  
Dan-Jun Song ◽  
Jin-Peng Tan ◽  
Ya Cao ◽  
...  

Objectives: Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant cancer. More than 70% of patients are diagnosed at an advanced stage. The aim of this study was to evaluate the diagnostic value of plasma miR-21, miR-122, and CA19-9, hoping to establish a novel model to improve the accuracy for diagnosing iCCA. Materials and methods: Plasma miR-21 and miR-122 were detected in 359 iCCA patients and 642 controls (healthy, benign liver lesions, other malignant liver tumors). All 1001 samples were allocated to training cohort (n = 668) and validation cohort (n = 333) in a chronological order. A logistic regression model was applied to combine these markers. Area under the receiver operating characteristic curve (AUC) was used as an accuracy index to evaluate the diagnostic performance. Results: Plasma miR-21 and miR-122 were significantly higher in iCCA patients than those in controls. Higher plasma miR-21 level was significantly correlated with larger tumor size (p = 0.030). A three-marker model was constructed by using miR-21, miR-122 and CA19-9, which showed an AUC of 0.853 (95% CI: 0.824–0.879; sensitivity: 73.0%, specificity: 87.4%) to differentiate iCCA from controls. These results were subsequently confirmed in the validation cohort with an AUC of 0.866 (0.825–0.901). The results were similar for diagnosing early (stages 0–I) iCCA patients (AUC: 0.848) and CA19-9negative iCCA patients (AUC: 0.795). Conclusions: We established a novel three-marker model with a high accuracy based on a large number of participants to differentiate iCCA from controls. This model showed a great clinical value especially for the diagnosis of early iCCA and CA19-9negative iCCA.

2019 ◽  
Vol 67 (5) ◽  
pp. 299-308 ◽  
Author(s):  
Xiaolei Jiao ◽  
Guiming Shu ◽  
Hui Liu ◽  
Qin Zhang ◽  
Zhe Ma ◽  
...  

Chemokines and their receptors have been proposed to play important roles in tumor progression and metastasis. To investigate their roles in the progression of primary and metastatic malignant liver tumors and their prognosis, we compared expression profiles of CXCL12/CXCR4, CCL20/CCR6, and CCL21/CCR7 in hepatocellular carcinoma (HCC) and colorectal liver metastases (CRLM). Immunohistochemistry was used to analyze the expression levels of the chemokine/chemokine receptor pairs in 29 HCC and 11 CRLM specimens and adjacent non-cancerous tissues, and correlations with clinicopathological variables and overall survival were determined. CCL20/CCR6 expression was higher in HCC than in adjacent non-cancerous tissues. High CCR6 expression in HCC was negatively associated with 5-year survival rate and was an independent prognostic factor for overall survival of HCC patients, whereas differences were not observed between CRLM and adjacent tissues. Furthermore, significantly higher expression of CCL21/CCR7 was found in CRLM than in HCC. In summary, the CCL20/CCR6 axis was elevated in HCC but not in CRLM, whereas the CCL21/CCR7 axis was elevated in CRLM but not in HCC.


1973 ◽  
pp. 166-170
Author(s):  
Sigmund H. Ein ◽  
Clinton A. Stephens

Author(s):  
V. E. Mukhin ◽  
Yu. S. Konstantinova ◽  
R. R. Gimadiev ◽  
N. V. Mazurchik

Primary liver tumors are one of the most common types of malignant neoplasms. Surgical excision is still the most effective treatment in the early stages of the disease, however in most cases early diagnosis is difficult. Moreover, even if the treatment is carried out according to a radical program, the risk of relapse remains extremely high. In this regard, the search for new strategies for the treatment of liver malignancies that differ from traditional methods of treatment is not terminated. One of such promising approaches is immunotherapy. The present review is devoted to the current understanding of the mechanisms of action and the available clinical experience in the use of immunotherapy approaches in the treatment of liver malignancies. Combining different types of immunotherapy or combining immunotherapy with traditional therapeutic approaches can facilitate a synergistic effect and contribute to the development of personalized medicine.


Author(s):  
Suyash S. Kulkarni ◽  
Nitin Sudhakar Shetty ◽  
Shashank Mishra ◽  
David Narayan

2014 ◽  
Vol 38 (5) ◽  
pp. 1288-1293 ◽  
Author(s):  
Kengo Ohta ◽  
Masashi Shimohira ◽  
Shigeru Sasaki ◽  
Hiromitsu Iwata ◽  
Hiroko Nishikawa ◽  
...  

2015 ◽  
Vol 113 (2) ◽  
pp. 130-134 ◽  
Author(s):  
Nisar Zaidi ◽  
Alexis Okoh ◽  
Hakan Yigitbas ◽  
Pinar Yazici ◽  
Noaman Ali ◽  
...  

2002 ◽  
Vol 6 (2) ◽  
pp. 527-554 ◽  
Author(s):  
Arief A Suriawinata ◽  
Swan N Thung

2012 ◽  
Vol 21 (3) ◽  
pp. 245-254 ◽  
Author(s):  
Joshua N. Honeyman ◽  
Michael P. La Quaglia

Sign in / Sign up

Export Citation Format

Share Document